Pregabalin for Chiari-like Malformation and Syringomyelia Pain in Dogs

Bottom line

• Chiari-like malformation (CM) and syringomyelia (SM) is a disease complex associated with neuropathic pain that commonly affects Cavalier King Charles Spaniels and several small brachycephalic breeds.[1][2]
• In a randomized, double-blinded, placebo-controlled crossover study, pregabalin significantly reduced owner-assessed clinical-sign scores in dogs with CM/SM compared with both baseline and placebo.[1]
• A long-term cohort of 48 Cavalier King Charles Spaniels found that clinical signs suggestive of neuropathic pain progressed in roughly three-quarters of affected dogs over a mean follow-up of about 39 months.[2]
• Gabapentinoids (pregabalin and gabapentin) are among the most frequently used medical treatments for CM/SM-associated neuropathic pain in dogs, though comparative evidence remains limited.[2][3]
• This page summarizes the published evidence for licensed veterinary professionals; it is not a dosing guide, and all prescribing should follow current formularies and clinical judgment.

Drug facts

• Class: Gabapentinoid; anticonvulsant used analgesically for neuropathic pain
• Route: Oral
• Use in dogs: Extra-label for neuropathic pain, including CM/SM-associated pain; gabapentinoids are widely reported in the CM/SM literature[2][3]
• Dosing: Not specified here; follow the current prescribing information and formulary for the individual patient

A specific patient with CM/SM pain?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=pregabalin-chiari-syringomyelia-pain-dogs

What the evidence shows

The condition: neuropathic pain in CM/SM

Chiari-like malformation describes a mismatch between the caudal fossa and its neural contents, and syringomyelia is the fluid-filled cavitation within the spinal cord that frequently accompanies it. The complex is strongly associated with neuropathic pain and is most recognized in Cavalier King Charles Spaniels, although it is reported across several small and toy breeds.[1][2] Characteristic signs include scratching toward the neck and shoulder (often without skin contact), facial rubbing, vocalization, and exercise intolerance.[2]

A prospective cohort study following 48 Cavalier King Charles Spaniels with CM and/or SM for a mean of approximately 39 months found that the overall severity of clinical signs increased over time, and that signs suggestive of neuropathic pain progressed in roughly three-quarters of dogs. A minority were static or improved, and most owners nonetheless rated their dog's quality of life as acceptable.[2] This natural-history picture frames CM/SM as a chronic, generally progressive pain condition rather than a self-limiting one.

Pregabalin: the controlled evidence

The most direct controlled evidence for pregabalin in this setting comes from a randomized, double-blinded, placebo-controlled crossover study conducted as part of the development and validation of the Chiari-like malformation and syringomyelia evaluation (CHASE) questionnaire. Twenty healthy dogs and thirty CM/SM-affected dogs were studied. Baseline owner-assessed CHASE scores were markedly higher in affected dogs than in healthy dogs, reflecting a higher burden of clinical signs.[1]

In the crossover comparison, CHASE scores decreased significantly with pregabalin relative to both baseline and placebo. The questionnaire differentiated the pregabalin condition from placebo with moderate discrimination, while quality-of-life measures, quantitative sensory testing, and activity monitoring did not show significant differences between conditions in this sample.[1] The headline clinical message is that a validated owner-reported outcome measure detected a pregabalin treatment effect that several objective measures did not, underscoring both the promise of pregabalin and the difficulty of quantifying neuropathic pain in dogs.

How pregabalin sits among the alternatives

Gabapentinoids are not the only agents used for CM/SM pain. A study of 90 Pomeranians with CM and/or SM compared amitriptyline with gabapentin and reported that amitriptyline produced a moderate, though not statistically significant, more favorable effect on clinical signs than gabapentin; adding furosemide to either treatment did not change the outcome.[3] Importantly, that analysis found the number and duration of clinical signs at presentation, rather than MRI grading, predicted response. Across the available studies, high-quality head-to-head comparative trials remain scarce, and gabapentinoids are used alongside other analgesic options without a clearly established hierarchy.[3]

Taken together, the literature supports pregabalin as a reasonable, evidence-informed option for CM/SM neuropathic pain, with the strongest controlled signal coming from the crossover study above, but it does not establish a single best agent or a one-size-fits-all approach.[1][3]

Measuring response

A recurring theme across these studies is measurement. Because CM/SM pain is subjective and fluctuating, validated owner-reported instruments such as CHASE may detect treatment effects more reliably than point-in-time clinical examination, sensory testing, or activity counts.[1] For practitioners, this argues for structured, repeated owner assessment when titrating or evaluating any analgesic in these patients.

How this fits clinical practice

This section summarizes the published evidence base for licensed practitioners and is not clinical guidance. CM/SM-associated neuropathic pain is typically chronic and progressive, so management is usually long-term and multimodal. Pregabalin has the most direct controlled evidence among the gabapentinoids for reducing owner-assessed signs, but comparative data against other analgesics are limited and no agent has been shown to halt structural progression.

Dosing for an individual patient must follow the current prescribing information and the clinician's judgment; this page does not provide dose recommendations. Structured, repeated owner-reported outcome measurement is a practical way to judge whether a given analgesic trial is helping. Where response is inadequate, the evidence supports considering alternative or adjunctive agents and reassessing the contribution of comorbidities, rather than assuming a fixed protocol.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=pregabalin-chiari-syringomyelia-pain-dogs

References

1. Valentino A, Moore SA, Fitzgerald S, et al. Development and validation of the Chiari-like malformation and syringomyelia evaluation: the CHASE questionnaire. J Vet Intern Med. 2026;40(1):aalaf040. https://pubmed.ncbi.nlm.nih.gov/41742505/
2. Plessas IN, Rusbridge C, Driver CJ, et al. Long-term outcome of Cavalier King Charles spaniel dogs with clinical signs associated with Chiari-like malformation and syringomyelia. Vet Rec. 2012;171(20):501. https://pubmed.ncbi.nlm.nih.gov/23100307/
3. Maat RT, van Heusden K, Hoogervorst-Spek L, et al. The effectiveness of amitriptyline and gabapentin in treating Pomeranians with Chiari-like malformation and/or syringomyelia. Animals (Basel). 2025;15(7):992. https://pubmed.ncbi.nlm.nih.gov/40218385/

Changelog

• 2026-06-05: First published.

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile